212 related articles for article (PubMed ID: 22339956)
1. [Analysis of prognostic risk factors in patients with diffuse large B-cell lymphoma].
Yu ZP; Ding JH; Chen BA; Gao C; Wang LL; Chen Z
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):830-5. PubMed ID: 22339956
[TBL] [Abstract][Full Text] [Related]
2. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
3. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics, cell origin and prognosis of primary gastrointestinal diffuse large B-cell lymphoma: a report of 40 cases].
Yang YL; Wang J; Zhao LZ; Gao ZF; Jing HM; Ke XY
Ai Zheng; 2008 Jun; 27(6):636-41. PubMed ID: 18570740
[TBL] [Abstract][Full Text] [Related]
5. [Research on prognostic factors in large-cell lymphomas].
Gandarillas MA; Conde E; Mazorra F; Cuadrado MA; Baro J; Garijo J; Recio M; Richard C; Iriondo A; Castro F
Med Clin (Barc); 1995 Apr; 104(16):601-7. PubMed ID: 7752710
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic factors analysis for R-CHOP regimen therapy in diffuse large B cell lymphoma].
Shen Y; Yao Y; Li JM; Chen QS; You JH; Zhao HJ; Chen S; Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):252-7. PubMed ID: 18843980
[TBL] [Abstract][Full Text] [Related]
7. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
[TBL] [Abstract][Full Text] [Related]
8. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic factors in low-grade lymphoma].
Gandarillas MA; Conde E; Mazorra F; Cuadrado MA; Baro J; Garijo J; Recio M; Richard C; Iriondo A; Zubizarreta A
Sangre (Barc); 1998 Jun; 43(3):185-90. PubMed ID: 9741223
[TBL] [Abstract][Full Text] [Related]
10. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
11. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified: a report of 78 cases].
Yu YX; Shi YK; He XH; Zhou LQ; Zhou SY; Dong M; Feng FY; Sun Y
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2714-6. PubMed ID: 18167252
[TBL] [Abstract][Full Text] [Related]
13. [Prognosis of primary non-Hodgkin's lymphoma of the breast].
Guo HY; Zhao XM; Cao JN; Hu XC; Yin JL; Hong XN; Li J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):200-2. PubMed ID: 18756936
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome.
Zaja F; Russo D; Silvestri F; Fanin R; Damiani D; Infanti L; Salmaso F; Mariuzzi L; Di Loreto C; Baccarani M
Haematologica; 1997; 82(2):171-7. PubMed ID: 9175321
[TBL] [Abstract][Full Text] [Related]
15. [Combination of rituximab with autologous peripheral blood stem cell transplantation for treatment of diffuse large B-cell lymphoma: a single-center experience].
Liang ZY; Cen XN; Qiu ZX; Ou JP; Wang WS; Xu WL; Li Y; Wang MJ; Dong YJ; Wang LH; Yin Y; Sun YH; Liu W; Wang Q; Ren HY
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1033-7. PubMed ID: 23363798
[TBL] [Abstract][Full Text] [Related]
16. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
Sohn BS; Park I; Kim EK; Yoon DH; Lee SS; Kang BW; Jang G; Choi YH; Kim C; Lee DH; Kim S; Huh J; Suh C
Bone Marrow Transplant; 2009 Sep; 44(5):287-93. PubMed ID: 19234508
[TBL] [Abstract][Full Text] [Related]
18. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
[TBL] [Abstract][Full Text] [Related]
19. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
[No Abstract] [Full Text] [Related]
20. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
